Work

Therapeutic potential of the heme oxygenase-1 inducer hemin against Ebola virus infection.

Year: 2016

Type: article

Abstract: Promising drugs to treat Ebola virus (EBOV) infection are currently being developed, but so far none has shown efficacy in clinical trials. Drugs that can stimulate host innate defense responses may retard the progression of EBOV disease. We report here the dramatic effect of hemin, the natural inducer of the heme catabolic enzyme heme oxygenase-1 (HO-1), in the reduction of EBOV replication. Treatment of primary monocyte-derived macrophages (MDM), Vero E6 cells, HeLa cells, and human foreskin fibroblasts (HFF1) with hemin reduced EBOV infection by >90%, and showed minimal toxicity to infected cells. Inhibition of HO-1 enzymatic activity and silencing HO-1 expression prevented the hemin-mediated suppression of EBOV infection, suggesting an important role for induction of this intracellular mediator in restricting EBOV replication. The inverse correlation between hemin-induced HO-1 and EBOV replication provides a potentially useful therapeutic modality based on the stimulation of an innate cellular response against Ebola infection.

Source: PubMed

Authors: Hanxia Huang, Krishnamurthy Konduru, Veronica Solovena, Zhao-Hua Zhou, Namita Kumari, Kazuyo Takeda, Sergei Nekhai, Sina Bavari, Gerardo G Kaplan, Kenneth M Yamada, Subhash Dhawan

Institutions: United States Food and Drug Administration, United States Army Medical Research Institute of Infectious Diseases, Howard University, National Institutes of Health, National Institute of Dental and Craniofacial Research

Language: English

Topic: Viral Infections and Outbreaks Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research, National Institute on Minority Health and Health Disparities

Awards: Center for Hemoglobin Research in Minorities (CHaRM), Craniofacial Developmental Dynamics, Second Generation Small Molecule Inhibitors of Botulinum Neurotoxins, Cell-Matrix Interactions and Migration, Targeting Cellular Processes to Counter the Effects of BoNT Intoxication, Sickle Cell Disease and Sickle Cell Trait Protection Against HIV-1-infection in Africans and African Americans, Biomedical Infrastructure for Health Disparities Research, District of Columbia Center for AIDS Research

OpenAlex ID: W2585697213

FWCI: 0.784

Cites: 20

Cited by: 12

Related to: 10